Invitae Sells Archer NGS Research Assays to Integrated DNA Technologies for $48M
IDT has acquired the VariantPlex, FusionPlex, LiquidPlex, and Immunoverse panels, powered by Invitae's anchored multiplex PCR (AMP) technology.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
Jury Awards ArcherDx, MGH $4.7M in Qiagen Patent Infringement Lawsuit
A federal jury ruled that various Qiagen sample prep products infringe a pair of US patents underlying ArcherDx's anchored multiplex PCR technology.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
Invitae Q3 Revenues Increase 22 Percent
The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate.